Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Mouse Sema3f ELISA Kit (AC3673)
Cat.#: ASET-2262
Specifications
Description Mouse Sema3f ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of mouse Sema3f concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Mouse Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.052 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 1.5-24 ng/mL Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1681 Mouse p75 NGF Receptor ELISA Kit (AC3092) Quantitative inquiry ASET-1227 Mouse Sorcs1 ELISA Kit (AC2638) Quantitative inquiry ASET-1190 Human Wnt10b ELISA Kit (AC2601) Quantitative inquiry ASET-2119 Human ACTH ELISA Kit (AC3530) Quantitative inquiry ASET-1597 Human Laminin ELISA Kit (AC3008) Quantitative inquiry ASET-1386 Mouse NMDAR1 ELISA Kit (AC2797) Quantitative inquiry ASET-2413 Mouse Has3 ELISA Kit (AC3824) Quantitative inquiry ASET-1960 Human NOX3 ELISA Kit (AC3371) Quantitative inquiry ASET-1611 Mouse Rln3 ELISA Kit (AC3022) Quantitative inquiry ASET-2449 Human TPH2 ELISA Kit (AC3860) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket